



## **For Immediate Release**

### **Experienced Healthcare Executive John L. Brooks, III, to Serve as WellDoc Advisor**

**Columbia, Maryland, January 18, 2018** – WellDoc®, a leading digital therapeutic company, announced today that John L. Brooks, III, a recognized life-sciences executive with more than 40 years of experience, will join the company’s team as a strategic advisor.

“We’re pleased that John has chosen to work with us as an advisor,” said WellDoc President and CEO Kevin McRaith. “His experience as a life sciences executive, specifically in the diabetes space, will be a great asset to WellDoc.”

Mr. Brooks is the Managing Director of Healthcare Capital LLC, an investment company that takes an advisory role with early-stage life sciences companies, with a specific focus on novel solutions for obesity, prediabetes and diabetes. Additionally, he is a Director at the Pittsburgh Life Sciences Greenhouse, which oversees two accelerators. He also serves on other corporate boards including Cellnovo Group SA, Thermalin, Inc., Hygieia, Inc., and the College Diabetes Network.

Before he joined Healthcare Capital, Mr. Brooks served as the President and CEO of the Joslin Diabetes Center, an NIH-designated Diabetes Research Center and non-profit recognized as a leader in diabetes research and treatment and affiliated with the Harvard Medical School.

Prior to his time at Joslin, Mr. Brooks co-founded Prism Venture Partners, a \$1.25 billion venture capital firm based in the Boston area. Previously, he was also a senior medical device executive with Pfizer and a senior manager with Arthur Andersen & Co.

“I’m excited for the opportunity to lend my experience to WellDoc,” said Mr. Brooks. “The company’s unique approach to the digital healthcare market is intriguing, and I’m looking forward to working with the team.”

A Massachusetts native, Mr. Brooks holds an MSBA in Accounting and Finance and BBA from the University of Massachusetts at Amherst. He is also a Certified Public Accountant.

#### **About WellDoc®**

WellDoc® is a leading digital therapeutic company revolutionizing chronic disease management to help transform lives. Our groundbreaking technology is guiding individuals through the complicated journey of living with chronic diseases, with a goal of improving their health and helping them to be more balanced. We are the first digital health company based on a life science business model with a foundation that is built on randomized clinical trials that demonstrate significant clinical outcomes. We have mastered diabetes management by taking an aggressive and innovative approach that utilizes sophisticated logic and precise algorithms, and integrates the most advanced mobile technology, behavioral insight, and diabetes education for those living with type 2 diabetes.



Our FDA-cleared, proven digital therapeutic, BlueStar®, provides real-time and timely individualized coaching and support, as well as diabetes educational tools that are actionable and personal. Our clinical evidence shows a 1.7 to 2.0-point mean A1C reduction for adults living with type 2 diabetes who used BlueStar®. In November 2017, the IQVIA Institute for Human Data Science (formerly Quintiles/IMS) named BlueStar the “top app” in clinical diabetes treatment. For more information, visit [www.welldoc.com](http://www.welldoc.com).

###

**Media Contact:**

Juliette Bogus

PressComm PR

Tel: +410.980.5687

Email: [juliette.bogus@gmail.com](mailto:juliette.bogus@gmail.com)